Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline)
Metabolic Health · Beta-2 adrenergic agonist
Tier C
High-risk evidence profile
Bottom line
Read Off Label grades Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) as C (4.6/10) based on moderate evidence, low-med benefit magnitude, and a med-high-risk safety profile.
Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.
WADA coverage: arformoterol, fenoterol, formoterol, higenamine, indacaterol, levosalbutamol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, tretoquinol/trimetoquinol, tulobuterol and vilanterol.
Studied, labeled, or reported-use context: Clinical inhaled dosing varies by agent; no enhancement dose — Rx asthma/COPD drugs or region-specific agents; WADA S3 prohibited except narrow permitted inhaled thresholds; not individualized guidance.
What the evidence says
WADA coverage: arformoterol, fenoterol, formoterol, higenamine, indacaterol, levosalbutamol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, tretoquinol/trimetoquinol, tulobuterol and vilanterol. Clenbuterol remains its own row because bodybuilding/fat-loss use is distinct and common.
Mechanism
Beta-2 agonists bronchodilate and at systemic/high doses may affect power, sprint output, lipolysis and lean mass; allowed inhaled therapeutic thresholds differ from prohibited systemic/performance use.
Studied, labeled, or reported dose & route
Clinical inhaled dosing varies by agent; no enhancement dose
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline)'s effects?
- Read Off Label rates the evidence for Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) as Moderate and the benefit magnitude as low-med, producing an overall grade of C (4.6/10). WADA coverage: arformoterol, fenoterol, formoterol, higenamine, indacaterol, levosalbutamol, olodaterol, procaterol, reproterol, salbutamol, salmeterol, terbutaline, tretoquinol/trimetoquinol, tulobuterol and vilanterol.
- What safety findings are reported for Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline)?
- Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) has a med-high risk profile in the database. Med-High (tachycardia, tremor, hypokalemia, arrhythmia risk at high/systemic doses) Legal status: Rx asthma/COPD drugs or region-specific agents; WADA S3 prohibited except narrow permitted inhaled thresholds.
- What does the low Safety score for Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) represent?
- The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
- What doses or routes are reported for Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline)?
- Clinical inhaled dosing varies by agent; no enhancement dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Other beta-2 agonists (salbutamol / formoterol / salmeterol / terbutaline) work?
- Beta-2 agonists bronchodilate and at systemic/high doses may affect power, sprint output, lipolysis and lean mass; allowed inhaled therapeutic thresholds differ from prohibited systemic/performance use.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.